相关实验视频
Updated: Jul 17, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
10.1K
与CA-125和CA 19-9表达相关的分散大B细胞淋巴瘤的临床病理学特征和预后
Abd AlRahman Mohammad Foda1,2, Tarek Atia3,4, Hader I Sakr5,6
1Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Journal of evidence-based integrative medicine
|September 1, 2023
概括
碳水化合物抗原19-9 (CA 19-9) 在12%的扩散性大B细胞淋巴瘤 (DLBCL) 组织中异常表达,与贫血和性能状况相关,但与生存无关. 在DLBCL组织中没有检测到CA-125.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 免疫组织化学 免疫组织化学
背景情况:
- 碳水化合物抗原125 (CA-125) 和CA 19-9在某些上皮瘤,特别是卵巢和胰腺癌中表达.
- 以前的研究将血清CA-125水平与非霍奇金淋巴瘤 (NHL) 的预后不佳联系起来.
- 在扩散性大B细胞淋巴瘤 (DLBCL) 中,CA-125和CA 19-9的表达,未另有说明 (NOS),仍然在很大程度上没有特征.
研究的目的:
- 通过免疫组织化学 (IHC) 来研究CA-125和CA 19-9在节点DLBCLNOS组织中的表达.
- 确定CA-125和CA 19-9表达和DLBCLNOS患者临床病理特征之间的关联.
- 评估CA-125和CA 19-9表达与DLBCLNOS患者存活率的相关性.
主要方法:
- 组织微阵列 (TMA) 由65个DLBCL NOS病例构成.
- 对CA-125和CA 19-9进行了免疫组织化学染色,并以半量化方式得分.
- 使用统计分析来评估标记物表达,临床病理学数据和生存结果之间的关系.
主要成果:
- 在12%的DLBCLNOS病例中发现了异常的CA 19-9表达;CA-125没有表达.
- CA 19-9阳性与贫血 (75%的病例) 和表现状态1 (75%的病例) 有显著的相关性.
- 在CA 19-9表达和女性性别 (75%的阳性病例) 之间观察到一个显著的关联.
结论:
- CA 19-9在节点DLBCLNOS的一个子集中异常表达,与特定的临床因素相关,但与生存无关.
- 在DLBCL NOS中,CA 19-9表达不是一个独立的预后因素.
- 建议进行进一步的研究,以探索血清/组织CA 19-9水平与节点和节点外DLBCLNOS的临床病理特征之间的关系.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.6K
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.4K
相关概念视频
01:21Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K